Medistem, Inc. engages in the development and commercialization of adult stem cell therapies in the United States. The company is developing endometrial regenerative cell (ERC), a universal donor stem cell product that promotes new blood vessel formation (angiogenesis), reduce inflammation, regulate immune system function, and augment tissue repair and healing. It is developing ERCs to treat a range of diseases, including ischemic conditions, cardiovascular and neurological diseases, kidney failure, liver failure, pulmonary diseases, and orphan disease indications, as well as autoimmune diseases, such as type 1 diabetes. The company was formerly known as Medistem Laboratories, Inc. and changed its name to Medistem, Inc. in August 2008. Medistem, Inc. is headquartered in San Diego, California.
35 companies, 1 interpreter!
Insight, foresight and recommendation
SOLD to Intrexon (NYSE: XON). MEDS stockholders will receive $0.27 in cash and $1.08 worth of XON’s common stock, based on the 20-day volume-weighted average price of the stock immediately prior to closing. MEDS platform has been saved; having NOT being able to raise capital – having been on a “thin” string for a while - it was the only “play or option” left!
goneMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.